<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113179</article-id><article-id pub-id-type="publisher-id">ACM-41214</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_76591345.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  外用红色诺卡氏菌细胞壁骨架治疗宫颈高危型HPV持续感染的临床疗效及免疫效果评价
  Evaluation of Clinical Efficacy and Immune Effect of Nocardia Rubra Cell Wall Skeleton for External Use in the Treatment of Persistent Cervical HPV Infection
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>梁</surname><given-names>欢</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邹</surname><given-names>存华</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>程</surname><given-names>菡莹</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>朱</surname><given-names>瑞森</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>淑萍</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属青岛市妇女儿童医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>1241</fpage><lpage>1249</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨外用红色诺卡氏菌细胞壁骨架(红卡)治疗高危型人乳头瘤病毒(HPV)持续感染的临床疗效及免疫效果。方法：选取2019年5月~2020年5月青岛市妇女儿童医院诊治的80例宫颈高危型HPV持续感染患者作为研究对象，随机将其分成研究组和对照组，每组40例。研究组应用红卡治疗，对照组应用重组人干扰素α2b阴道泡腾片(金舒喜)联合保妇康栓治疗。比较两组患者的HPV转阴率、治疗有效率、治疗前后外周血免疫细胞水平变化、阴道灌洗液中免疫因子水平变化及不良反应的发生情况。结果：研究组临床治疗总有效率为76.92%，对照组47.37%，差异有统计学意义(P &lt; 0.05)。研究组患者的 HPV转阴率61.54%，对照组31.58%，差异有统计学意义(P &lt; 0.05)。两组治疗后CD4+T、CD4+/CD8+的数值均上升，较治疗前差异有统计学意义(P &lt; 0.05)，且上升程度研究组显著高于对照组，差异有统计学意义(P &lt; 0.05)，而CD8+T治疗前后两组患者均无明显差异(P &gt; 0.05)。两组治疗后阴道灌洗液中IL-2、IFN-γ、TNF-α浓度均升高，IL-4浓度均降低，较治疗前差异有统计学意义(P &lt; 0.05)，且研究组上述指标变化均显著高于对照组，差异有统计学意义(P &lt; 0.05)；而IL-6、IL-10治疗前后两组患者均无明显差异(P &gt; 0.05)。两组治疗均未发生严重的不良反应。结论：红卡可有效提高宫颈高危型HPV持续感染患者的转阴率，并能调节宫颈局部甚至机体的免疫功能，且无明显不良反应。
    Objective: To explore the clinical efficacy and immune effect of Nocardia rubra Cell Wall Skeleton for External Use (Nr-CWS) in the treatment of high-risk human papillomavirus (HPV) persistent infection. Methods: From May 2019 to May 2020, 80 patients with high-risk HPV persistent cervical infection who were diagnosed and treated at Qingdao Women and Children's Hospital were collected, and they were randomly divided into a study group and a control group with 40 cases in each group. The study group was treated with Nr-CWS, and the control group was treated with recombinant human interferon 2b vaginal effervescent tablets combined with Baofukangshuan. We compared the HPV conversion rate and effective rate of treatment in the two groups. We also analyze the changes of immune cell levels in peripheral blood and immune factor concentrations in vaginal lavage fluid, and the occurrence of adverse reactions. Results: The total effective rate was 76.92% in the study group and 47.37% in the control group, and the difference was statistically significant (P &lt; 0.05). The HPV conversion rate was 61.54% in the study group and 31.58% in the control group, and the difference was statistically significant (P &lt; 0.05). After treatment, the values of CD4+T and CD4+/CD8+ increased in both groups, with statistically significant difference compared with before treatment (P &lt; 0.05), and the degree of increase in the research group was significantly higher than that in the control group (P &lt; 0.05), while there was no significant difference in the two groups before and after CD8+T treatment (P &gt; 0.05). After treatment, the concentrations of IL-2, IFN- and TNF- in vaginal lavage fluid in both groups were increased, while the concentrations of IL-4 were decreased, with statistical significance compared with before treatment (P &lt; 0.05). The changes of the above indexes in the study group were significantly higher than those in the control group, with statistical significance (P &lt; 0.05). There was no significant difference between the two groups before and after the treatment of IL-6 and IL-10 (P &gt; 0.05). No serious adverse reactions occurred in the two groups, and they have high security. Conclusions: Nr-CWS can effectively improve the negative conversion rate of patients with high-risk HPV persistent infection of the cervix, and can regulate the local and even the body’s immune function, and there are no obvious adverse reactions. 
  
 
</p></abstract><kwd-group><kwd>外用红色诺卡氏菌细胞壁骨架(红卡)，高危型HPV感染，免疫细胞，免疫因子, Nocardia Rubra Cell Wall Skeleton for External Use (Nr-CWS)</kwd><kwd> High-Risk HPV Infection</kwd><kwd>
Immune Cells</kwd><kwd> Immune Factors</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨外用红色诺卡氏菌细胞壁骨架(红卡)治疗高危型人乳头瘤病毒(HPV)持续感染的临床疗效及免疫效果。方法：选取2019年5月~2020年5月青岛市妇女儿童医院诊治的80例宫颈高危型HPV持续感染患者作为研究对象，随机将其分成研究组和对照组，每组40例。研究组应用红卡治疗，对照组应用重组人干扰素α2b阴道泡腾片(金舒喜)联合保妇康栓治疗。比较两组患者的HPV转阴率、治疗有效率、治疗前后外周血免疫细胞水平变化、阴道灌洗液中免疫因子水平变化及不良反应的发生情况。结果：研究组临床治疗总有效率为76.92%，对照组47.37%，差异有统计学意义(P &lt; 0.05)。研究组患者的 HPV转阴率61.54%，对照组31.58%，差异有统计学意义(P &lt; 0.05)。两组治疗后CD4<sup>+</sup>T、CD4<sup>+</sup>/CD8<sup>+</sup>的数值均上升，较治疗前差异有统计学意义(P &lt; 0.05)，且上升程度研究组显著高于对照组，差异有统计学意义(P &lt; 0.05)，而CD8<sup>+</sup>T治疗前后两组患者均无明显差异(P &gt; 0.05)。两组治疗后阴道灌洗液中IL-2、IFN-γ、TNF-α浓度均升高，IL-4浓度均降低，较治疗前差异有统计学意义(P &lt; 0.05)，且研究组上述指标变化均显著高于对照组，差异有统计学意义(P &lt; 0.05)；而IL-6、IL-10治疗前后两组患者均无明显差异(P &gt; 0.05)。两组治疗均未发生严重的不良反应。结论：红卡可有效提高宫颈高危型HPV持续感染患者的转阴率，并能调节宫颈局部甚至机体的免疫功能，且无明显不良反应。</p></sec><sec id="s2"><title>关键词</title><p>外用红色诺卡氏菌细胞壁骨架(红卡)，高危型HPV感染，免疫细胞，免疫因子</p></sec><sec id="s3"><title>Evaluation of Clinical Efficacy and Immune Effect of Nocardia Rubra Cell Wall Skeleton for External Use in the Treatment of Persistent Cervical HPV Infection</title><p>Huan Liang, Cunhua Zou, Hanying Cheng, Ruisen Zhu, Shuping Zhao<sup>*</sup></p><p>Qingdao Women and Children’s Hospital, Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/62-1572054x5_hanspub.png" /></p><p>Received: Feb. 17<sup>th</sup>, 2021; accepted: Mar. 5<sup>th</sup>, 2021; published: Mar. 25<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/62-1572054x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the clinical efficacy and immune effect of Nocardia rubra Cell Wall Skeleton for External Use (Nr-CWS) in the treatment of high-risk human papillomavirus (HPV) persistent infection. Methods: From May 2019 to May 2020, 80 patients with high-risk HPV persistent cervical infection who were diagnosed and treated at Qingdao Women and Children's Hospital were collected, and they were randomly divided into a study group and a control group with 40 cases in each group. The study group was treated with Nr-CWS, and the control group was treated with recombinant human interferon a2b vaginal effervescent tablets combined with Baofukangshuan. We compared the HPV conversion rate and effective rate of treatment in the two groups. We also analyze the changes of immune cell levels in peripheral blood and immune factor concentrations in vaginal lavage fluid, and the occurrence of adverse reactions. Results: The total effective rate was 76.92% in the study group and 47.37% in the control group, and the difference was statistically significant (P &lt; 0.05). The HPV conversion rate was 61.54% in the study group and 31.58% in the control group, and the difference was statistically significant (P &lt; 0.05). After treatment, the values of CD4<sup>+</sup>T and CD4<sup>+</sup>/CD8<sup>+</sup> increased in both groups, with statistically significant difference compared with before treatment (P &lt; 0.05), and the degree of increase in the research group was significantly higher than that in the control group (P &lt; 0.05), while there was no significant difference in the two groups before and after CD8<sup>+</sup>T treatment (P &gt; 0.05). After treatment, the concentrations of IL-2, IFN-g and TNF-a in vaginal lavage fluid in both groups were increased, while the concentrations of IL-4 were decreased, with statistical significance compared with before treatment (P &lt; 0.05). The changes of the above indexes in the study group were significantly higher than those in the control group, with statistical significance (P &lt; 0.05). There was no significant difference between the two groups before and after the treatment of IL-6 and IL-10 (P &gt; 0.05). No serious adverse reactions occurred in the two groups, and they have high security. Conclusions: Nr-CWS can effectively improve the negative conversion rate of patients with high-risk HPV persistent infection of the cervix, and can regulate the local and even the body’s immune function, and there are no obvious adverse reactions.</p><p>Keywords:Nocardia Rubra Cell Wall Skeleton for External Use (Nr-CWS), High-Risk HPV Infection, Immune Cells, Immune Factors</p><disp-formula id="hanspub.41214-formula24"><graphic xlink:href="//html.hanspub.org/file/62-1572054x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/62-1572054x8_hanspub.png" /> <img src="//html.hanspub.org/file/62-1572054x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>宫颈癌是常见的妇科恶性肿瘤之一，其发病率也呈逐年上升趋势，严重影响患者的生活质量及身心健康，更加重其与国家和社会的经济负担。人乳头瘤病毒(HPV)主要通过性接触进行传播 [<xref ref-type="bibr" rid="hanspub.41214-ref1">1</xref>]，可分为低危型和高危型两大类，低危型常导致低级别鳞状上皮内病变(LSIL)及良性生殖器疣等；而高危型多会导致高级别鳞状上皮内病变(HSIL)和宫颈癌 [<xref ref-type="bibr" rid="hanspub.41214-ref2">2</xref>]，其中高危型HPV 16、18型可导致约70%的宫颈癌发生 [<xref ref-type="bibr" rid="hanspub.41214-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.41214-ref4">4</xref>]。同种亚型HPV连续感染1年及以上称为持续感染，临床研究表明感染HPV后90%的患者能够通过自身免疫反应清除体内HPV，仅有少部分HPV会持续感染并进一步导致机体发生皮肤黏膜病变 [<xref ref-type="bibr" rid="hanspub.41214-ref5">5</xref>]，并可能进一步发展成为宫颈上皮内瘤变，甚至宫颈癌。国内外研究均表明：高危型HPV的持续感染是导致宫颈癌的发生、发展及复发的关键因素 [<xref ref-type="bibr" rid="hanspub.41214-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.41214-ref7">7</xref>]。因此，尽早发现及治疗HPV感染及宫颈癌前病变，是预防和降低宫颈癌发病率的关键。HPV感染多与人体免疫功能降低有关，常常伴随人体局部或全身免疫状态的低下或缺陷 [<xref ref-type="bibr" rid="hanspub.41214-ref8">8</xref>]。目前临床上多通过测定外周血淋巴细胞比值及局部免疫因子的水平了解患者的局部甚至全身免疫情况。针对高危型HPV持续感染者，临床上采用重组人干扰素、中药制剂及物理治疗等多种方法，但多以缓解症状为治疗原则 [<xref ref-type="bibr" rid="hanspub.41214-ref9">9</xref>]，HPV清除效果欠佳，且对各种治疗方法的免疫效果评价较少。红卡作为一种非特异性免疫调节剂，可对患者局部甚至全身免疫系统起到调节作用，因此，本次研究旨在探讨红卡治疗宫颈高危型HPV持续感染的临床疗效及免疫效果。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>选取2018年9月~2019年11月青岛市妇女儿童医院妇科诊治的80例宫颈高危型HPV感染的患者作为研究对象，随机数字表法将其分成研究组和对照组，每组40例，研究组给予红卡治疗，对照组给予金舒喜联合保妇康栓治疗。纳入标准：患者宫颈高危型HPV感染病程超过1年，人乳头瘤病毒脱氧核糖核酸非扩增定性检测(HPVE6E7)阳性，妇科液基细胞学检查(TCT)提示非典型鳞状细胞意义不明确(ASC-US)或未见明显异常，转行阴道镜者病理活检结果提示宫颈炎症；年龄25~50岁，且有性生活史；入组前6个月内没有接受过任何宫颈病变相关治疗；获得知情同意并自愿进入本次研究。排除标准：妊娠期及哺乳期女性；霉菌性阴道炎等各种阴道疾病；宫颈癌前病变、宫颈癌患者；合并其他恶性肿瘤或放化疗史患者；高血压、糖尿病及甲状腺疾病及其他免疫系统疾病患者；长期或近半年内应用皮质类固醇激素及免疫抑制剂的患者; 严重心、肝、肾脏及造血系统功能异常的患者；处于各种急性炎症期或者慢性疾病急性发作期。研究组年龄范围25~46岁，平均(33.72 &#177; 4.53)岁；平均孕(2.74 &#177; 1.33)次，产(1.33 &#177; 0.70)次，感染高危型HPV病程(15.54 &#177; 2.91)月；40例患者中11 (27.50%)例为HPV 16型感染，7 (17.50%)例为HPV 18/45型感染，9 (22.50%)例为HPV其他高危型感染，15 (37.50%)例为多型感染。对照组患者年龄范围26~49岁，平均(33.97 &#177; 4.76)岁；平均孕(2.66 &#177; 1.36)次，产(1.29 &#177; 0.73)次，感染高危型HPV病程(16.05 &#177; 2.82)月；40例患者中8 (20.00%)例为HPV 16型感染，9 (22.50%)例为HPV 18/45型感染，10 (25.00%)例为HPV其他高危型感染，13 (32.50%)例为多型感染。两组患者的年龄、孕产次及HPV感染时间及感染HPV型别等一般资料比较，差异无统计学意义(P &gt; 0.05)，具有可比性。该项研究的所有患者及其家属均已知情同意且签署知情同意书，并经过医院医学伦理委员会审核批准。</p></sec><sec id="s6_2"><title>2.2. 方法</title><p>对照组患者给予金舒喜联合保妇康栓治疗，选取月经干净后第3天开始用药，给予保妇康栓[生产厂家：海南碧凯药业有限公司；国药准字：Z46020058]睡前将药物推至阴道深处，1个/天；重组人干扰素α2b阴道泡腾胶囊[生产厂家：北京凯因科技股份有限公司；国药准字：S20120019]阴道用药，隔天1次，50万IU/次，共9天；两者交替用药。实验组患者给予红卡(国药准字S20030009)治疗，月经干净后第三天开始，60 ug/支，2支/次，隔天一次，10次为一个疗程；用药前先清除外阴、阴道及宫颈分泌物，小毛刷着重于宫颈管及宫颈表面的制造微创面(轻微渗血状态)，1 mL注射器放射状划伤宫颈，深度约2~3 mm，第1支红卡用1 mL生理盐水溶解，巴氏滴管吸取后插到宫颈管(不超过1 cm)推药，确保宫颈管内被药液充满，在吸取溢出阴道内的药液冲洗穹窿和宫颈表面；第2支药品以2 mL生理盐水溶解，尾线棉球沾取药液，尽量大面积的接触、紧密贴合宫颈、穹隆或病变部位，棉球伸出留尾线伸出阴道口，上完药后患者平躺15~20分钟左右，带尾线棉球在体内保留24小时后患者自行取出即可。要求两组患者经期不予治疗，且治疗过程中禁盆浴及性生活，禁止其他针对宫颈病变的治疗。两组患者治疗前及治疗后3月复查妇科液基细胞学检查(TCT)、人乳头瘤病毒脱氧核糖核酸非扩增定性检测(HPV E6E7)，必要者转行阴道镜宫颈病理活检；并于月经干净1周内抽取空腹外周血检测外周血淋巴细胞亚群、采集阴道灌洗液测定免疫因子，收集资料进行整理分析。</p></sec><sec id="s6_3"><title>2.3. 观察指标及评价标准</title><sec id="s6_3_1"><title>2.3.1. HPV治疗有效率</title><p>治愈指治疗后复查HPV E6E7转为阴性，TCT无进展，治愈率即HPV转阴率；好转指治疗后复查HPV未转阴但高危型HPV的感染种类减少，TCT未进展，转诊阴道镜者病理结果未见明显异常或宫颈慢性炎症。无效：治疗后复查HPV E6E7未转阴，或TCT进展为ASC-US、LSIL、高级别鳞状上皮内病变(HSIL)，转诊阴道镜者病理结果提示宫颈鳞状上皮内瘤变甚至宫颈癌。</p></sec><sec id="s6_3_2"><title>2.3.2. 治疗前后外周血免疫细胞变化水平</title><p>治疗前及治疗后3个月分别于月经干净1周内抽取采集患者清晨空腹静脉血液5 mL，于室温20℃~25℃下进行保存，采用流式细胞仪(型号：BD FACSCanto II)对血液样本进行检测(采血24小时以内)，检测外周血CD4<sup>+</sup>T，CD8<sup>+</sup>T，CD4<sup>+</sup>/CD8<sup>+</sup>，并比较治疗前后以上指标变化情况。</p></sec><sec id="s6_3_3"><title>2.3.3. 治疗前后阴道灌洗液中免疫因子变化</title><p>治疗前及治疗后3月分别于月经干净1周内收集阴道灌洗液，用5 mL生理盐水反复冲洗宫颈及阴道上段，吸取灌洗液以1500转/分钟离心10分钟，取上清液保存于−70℃备用，放置室温后以酶联免疫吸附法检测并计算样本中白介素-2 (IL-2)、白介素-4 (IL-4)、白介素-6 (IL-6)、白介素-10 (IL-10)、肿瘤坏死因子-α (TNF-α)、干扰素-γ (IFN-γ)的浓度。</p></sec><sec id="s6_3_4"><title>2.3.4. 两组患者的不良反应</title><p>随访统计患者治疗期间有无发热，有无阴道灼热感，有无阴道流血流液及阴道分泌物增多及异味，有无外阴及阴道瘙痒、腰酸、下腹坠痛等不适，记录不良反应出现、持续及消失的时间。</p></sec></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>采用SPSS 26.0统计学软件进行数据分析，计数资料采用例数和百分比(%)表示，计量资料用均数 &#177;标准差( x &#175; &#177; s)表示。计数资料采用秩和检验；两组内治疗前后比较采用配对样本t检验；两组间比较采用独立样本t检验，以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><p>本次研究中共80例患者，研究组有1例患者(HPV 16阳性)未按要求完成全疗程治疗，对照组中有1例患者(多型HPV感染)未按要求随访检查，1例患者(HPV 18/45阳性)治疗同时自行口服中药，以上三位患者均剔除出本次研究。其余患者：研究组共39例、对照组共38例，均按要求完成治疗随访且过程顺利。</p><sec id="s7_1"><title>3.1. 两组患者HPV转阴率及治疗有效率</title><p>临床治疗总有效率研究组为76.92%，对照组为47.37%，HPV转阴率研究组为61.54%，对照组为31.58%，两组秩和检验得Z = −2.834，P = 0.005，差异有统计学意义(P &lt; 0.05)，见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of cervical HPV infection between the two groups after treatmen</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >治愈</th><th align="center" valign="middle" >好转</th><th align="center" valign="middle" >无效</th><th align="center" valign="middle" >秩和范围</th><th align="center" valign="middle" >秩平均值</th><th align="center" valign="middle" >秩和</th><th align="center" valign="middle" >有效率(%)</th></tr></thead><tr><td align="center" valign="middle" >研究组</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >1~39</td><td align="center" valign="middle" >32.46</td><td align="center" valign="middle" >1266</td><td align="center" valign="middle" >76.92<sup>* </sup></td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >40~77</td><td align="center" valign="middle" >45.71</td><td align="center" valign="middle" >1737</td><td align="center" valign="middle" >47.37</td></tr></tbody></table></table-wrap><p>表1. 两组患者治疗后复查宫颈HPV情况比较</p><p>注：<sup>*</sup>表示与对照组比较差异有统计学意义(P &lt; 0.05)。</p></sec><sec id="s7_2"><title>3.2. 两组患者治疗前后外周血淋巴细胞亚群变化比较</title><p>收集治疗前后两组患者外周血CD4<sup>+</sup>T、CD8<sup>+</sup>T及CD4<sup>+</sup>/CD8<sup>+</sup>的数值进行统计分析，上述指标治疗后减去治疗前得出差值，应用差值进行数据分析(见表2)。治疗前，两组患者以上指标比较，差异无统计学意义(P &gt; 0.05)。治疗后两组患者CD4<sup>+</sup>T占比及CD4<sup>+</sup>/CD8<sup>+</sup>数值均较治疗前升高，且差异有统计学意义(P &lt; 0.05)，而CD8<sup>+</sup>T占比治疗前后差异无统计学意义(P &gt; 0.05)。治疗后，研究组CD4<sup>+</sup>T占比及CD4<sup>+</sup>/CD8<sup>+</sup>数值升高的程度明显高于对照组，差异有统计学意义(P &lt; 0.05) (详见表2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of changes of CD4+T, CD8+T and CD4+/CD8+ between the two groups before and after treatment ( x &#175; &#177; s , %</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" ></th><th align="center" valign="middle" >CD4<sup>+</sup>T</th><th align="center" valign="middle" >CD8<sup>+</sup>T</th><th align="center" valign="middle" >CD4<sup>+</sup>/CD8<sup>+</sup></th></tr></thead><tr><td align="center" valign="middle"  rowspan="5"  >研究组</td><td align="center" valign="middle"  rowspan="5"  >39</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >30.94 &#177; 2.85</td><td align="center" valign="middle" >30.50 &#177; 2.51</td><td align="center" valign="middle" >1.02 &#177; 0.11</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >40.04 &#177; 2.41</td><td align="center" valign="middle" >30.71 &#177; 2.08</td><td align="center" valign="middle" >1.31 &#177; 0.15</td></tr><tr><td align="center" valign="middle" >差值</td><td align="center" valign="middle" >9.10 &#177; 2.35</td><td align="center" valign="middle" >0.21 &#177; 1.74</td><td align="center" valign="middle" >0.29 &#177; 0.10</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" >−24.187</td><td align="center" valign="middle" >−0.761</td><td align="center" valign="middle" >−18.821</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.451</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle"  rowspan="5"  >对照组</td><td align="center" valign="middle"  rowspan="5"  >38</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >31.18 &#177; 3.39</td><td align="center" valign="middle" >31.37 &#177; 2.70</td><td align="center" valign="middle" >1.00 &#177; 0.12</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >36.46 &#177; 3.74</td><td align="center" valign="middle" >30.86 &#177; 2.60</td><td align="center" valign="middle" >1.18 &#177; 0.13</td></tr><tr><td align="center" valign="middle" >差值</td><td align="center" valign="middle" >5.28 &#177; 3.40</td><td align="center" valign="middle" >−0.51 &#177; 0.71</td><td align="center" valign="middle" >0.19 &#177; 0.11</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" >−9.568</td><td align="center" valign="middle" >1.844</td><td align="center" valign="middle" >−10.632</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.073</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >组间对比</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >t</td><td align="center" valign="middle" >5.750</td><td align="center" valign="middle" >1.838</td><td align="center" valign="middle" >4.533</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.070</td><td align="center" valign="middle" >0.000</td></tr></tbody></table></table-wrap><p>表2. 两组患者治疗前后CD4<sup>+</sup>T及CD8<sup>+</sup>T、CD4<sup>+</sup>/CD8<sup>+</sup>变化比较( x &#175; &#177; s , %)</p></sec><sec id="s7_3"><title>3.3. 两组患者治疗前后阴道灌洗液免疫因子变化情况</title><p>收集治疗前后两组患者阴道灌洗液中IL-2、IL-4、IL-6、IL-10、IFN-γ、TNF-α浓度进行统计分析；上述指标治疗后减去治疗前得出差值，应用差值进行数据分析(见表3)。治疗前，两组患者以上指标比较，差异无统计学意义(P &gt; 0.05)。治疗后两组患者IL-2、IFN-g、TNF-α浓度均升高，IL-4浓度均降低，差异均有统计学意义(P &lt; 0.05)，而治疗前后两组IL-6、IL-10浓度差异均无统计学意义(P &gt; 0.05)；治疗后，研究组IL-2、IFN-γ、TNF-α浓度升高的程度明显高于对照组，IL-4浓度降低程度明显高于对照组，差异有统计学意义(P &lt; 0.05) (详见表3)。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of changes of IL-2、IL-4、IL-6、IL-10、IFN-g and TNF-α before and after treatment between the two groups ( x &#175; &#177; s , ng/l</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  >指标组别</th><th align="center" valign="middle" >IL-2</th><th align="center" valign="middle" >IL-4</th><th align="center" valign="middle" >IL-6</th><th align="center" valign="middle" >IL-10</th><th align="center" valign="middle" >IFN-g</th><th align="center" valign="middle" >TNF-α</th></tr></thead><tr><td align="center" valign="middle"  rowspan="5"  >研究组 (39例)</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >88.16 &#177; 4.58</td><td align="center" valign="middle" >17.27 &#177; 2.23</td><td align="center" valign="middle" >1.71 &#177; 0.43</td><td align="center" valign="middle" >8.21 &#177; 1.38</td><td align="center" valign="middle" >29.29 &#177; 2.57<sup> </sup></td><td align="center" valign="middle" >26.32 &#177; 3.01</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >97.00 &#177; 4.25</td><td align="center" valign="middle" >12.79 &#177; 2.19</td><td align="center" valign="middle" >1.69 &#177; 0.38</td><td align="center" valign="middle" >8.00 &#177; 1.06</td><td align="center" valign="middle" >36.68 &#177; 3.22</td><td align="center" valign="middle" >32.35 &#177; 3.02</td></tr><tr><td align="center" valign="middle" >差值</td><td align="center" valign="middle" >8.84 &#177; 3.37</td><td align="center" valign="middle" >−4.48 &#177; 2.39</td><td align="center" valign="middle" >−0.016 &#177; 0.41</td><td align="center" valign="middle" >−0.21 &#177; 1.16</td><td align="center" valign="middle" >7.54 &#177; 3.53</td><td align="center" valign="middle" >6.02 &#177; 2.83</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" >−16.394</td><td align="center" valign="middle" >11.674</td><td align="center" valign="middle" >0.24</td><td align="center" valign="middle" >1.142</td><td align="center" valign="middle" >−14.648</td><td align="center" valign="middle" >−13.297</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.812</td><td align="center" valign="middle" >0.261</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle"  rowspan="5"  >对照组 (38例)</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >87.49 &#177; 5.21</td><td align="center" valign="middle" >17.24 &#177; 2.23</td><td align="center" valign="middle" >1.70 &#177; 0.47</td><td align="center" valign="middle" >8.21 &#177; 1.52</td><td align="center" valign="middle" >29.17 &#177; 2.27</td><td align="center" valign="middle" >26.17 &#177; 2.55</td></tr><tr><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >92.15 &#177; 5.04</td><td align="center" valign="middle" >14.52 &#177; 2.05</td><td align="center" valign="middle" >1.69 &#177; 0.40</td><td align="center" valign="middle" >7.90 &#177; 1.30</td><td align="center" valign="middle" >33.23 &#177; 2.32</td><td align="center" valign="middle" >28.78 &#177; 2.36</td></tr><tr><td align="center" valign="middle" >差值</td><td align="center" valign="middle" >4.66 &#177; 3.78</td><td align="center" valign="middle" >−2.71 &#177; 1.72</td><td align="center" valign="middle" >−0.002 &#177; 0.43</td><td align="center" valign="middle" >−0.31 &#177; 1.11</td><td align="center" valign="middle" >4.06 &#177; 2.06</td><td align="center" valign="middle" >2.61 &#177; 2.42</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" >−7.064</td><td align="center" valign="middle" >9.727</td><td align="center" valign="middle" >0.034</td><td align="center" valign="middle" >1.730</td><td align="center" valign="middle" >−12.153</td><td align="center" valign="middle" >−6.650</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.973</td><td align="center" valign="middle" >0.092</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >组间对比</td><td align="center" valign="middle" >t</td><td align="center" valign="middle" >5.117</td><td align="center" valign="middle" >−3.704</td><td align="center" valign="middle" >−0.141</td><td align="center" valign="middle" >0.381</td><td align="center" valign="middle" >5.290</td><td align="center" valign="middle" >5.682</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.888</td><td align="center" valign="middle" >0.704</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td></tr></tbody></table></table-wrap><p>表3. 两组患者治疗前后IL-2、IL-4、IL-6、IL-10、IFN-g、TNF-α变化比较( x &#175; &#177; s , ng/l)</p></sec><sec id="s7_4"><title>3.4. 两组患者不良反应发生情况</title><p>治疗过程中，两组患者均未见明显不良反应，总体而言，红卡及金舒喜联合保妇康栓治疗宫颈HPV持续感染均具有较高安全性。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>HPV是一种双链DNA病毒，感染人体后会将基因随机整合到宿主细胞的DNA中 [<xref ref-type="bibr" rid="hanspub.41214-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.41214-ref11">11</xref>]，削弱E2基因的表达，E2蛋白表达减少直接降低对于HPV E6E7基因表达的抑制作用 [<xref ref-type="bibr" rid="hanspub.41214-ref12">12</xref>]，使E6E7过度表达，最终导致被HPV感染的细胞无限增殖甚至癌变 [<xref ref-type="bibr" rid="hanspub.41214-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.41214-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.41214-ref14">14</xref>]。HPV感染人体后，非特异性免疫细胞(包括中性粒细胞、巨噬细胞、淋巴细胞等)首先做出应答，产生白介素类、干扰素类和肿瘤坏死因子等炎症因子并激活自然杀死(NK)细胞和其他免疫细胞 [<xref ref-type="bibr" rid="hanspub.41214-ref15">15</xref>]。之后机体免疫系统对抗HPV感染的过程中，细胞免疫起主导作用，树突细胞可标记HPV抗原，并将其分别递呈给CD8<sup>+</sup>T细胞和 CD4<sup>+</sup>T细胞，CD8<sup>+</sup>T细胞分化为细胞毒T细胞清除细胞内的HPV，而CD4<sup>+</sup>T细胞分化为调节型T细胞抑制细胞毒T细胞的活性 [<xref ref-type="bibr" rid="hanspub.41214-ref16">16</xref>]。正常情况下，机体的CD4<sup>+</sup>/CD8<sup>+</sup>处于平衡状态，从宫颈炎、低级别宫颈上皮内瘤变、高级别宫颈上皮内瘤变至宫颈癌中，外周血CD4<sup>+</sup>T细胞数量逐渐减少而CD8<sup>+</sup>T细胞的数量逐渐增多，人体T淋巴细胞亚群的紊乱程度也不断加剧，CD4<sup>+</sup>/CD8<sup>+</sup>的比值呈现出逐渐下降甚至倒置的趋势 [<xref ref-type="bibr" rid="hanspub.41214-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.41214-ref18">18</xref>]，这一现象也是机体细胞免疫削弱的重要标志 [<xref ref-type="bibr" rid="hanspub.41214-ref19">19</xref>]。</p><p>红卡作为一种非特异性免疫调节剂，主要成分为胞壁酸、阿拉伯半乳聚糖和粘肽(肽聚糖)等，其一方面可以促进巨噬细胞分化为M1型，通过非特异性免疫反应清除HPV感染 [<xref ref-type="bibr" rid="hanspub.41214-ref20">20</xref>]；一方面可促进抗原提呈激活CD4<sup>+</sup>T细胞，CD4<sup>+</sup>T细胞被活化后可分化为辅助性T细胞1 (Th1)和辅助性细胞2 (Th2)，Th1细胞主要表达TNF-α、IL-2和IFN-γ，主导细胞免疫，Th2主要表达IL-10、IL-6和IL-4，主导体液免疫，共同参与免疫调节和免疫应答 [<xref ref-type="bibr" rid="hanspub.41214-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.41214-ref22">22</xref>]，通过特异性免疫反应清除HPV感染，杀伤宫颈上皮异型细胞、抑制宫颈低级鳞状上皮内病变进展为高级别病变，促进HPV感染细胞逆转为正常细胞 [<xref ref-type="bibr" rid="hanspub.41214-ref20">20</xref>]，从而发挥抗病毒的作用。李亚光等人对40例高危型HPV感染者(病程 ≥ 6月)给予派特灵(红卡制剂)治疗后HPV转阴率达87.5% [<xref ref-type="bibr" rid="hanspub.41214-ref23">23</xref>]，而本次研究中，红卡治疗后转阴率较上述研究偏低，考虑可能与宫颈高危型HPV感染的持续时间有关，本次研究均为HPV感染持续超过1年的患者，感染时间越长，宫颈病变程度越重，HPV清除会越困难，转阴率势必会有所降低。本次红卡治疗外周血中CD4<sup>+</sup>T占比及CD4<sup>+</sup>/CD8<sup>+</sup>比值均上升，目前对于红卡对外周血免疫细胞的现有研究缺乏临床数据印证。本次研究红卡治疗前后检测阴道灌洗液中IL-2、IFN-γ、TNF-α浓度上升，IL-4浓度降低，与已发表的相关研究 [<xref ref-type="bibr" rid="hanspub.41214-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.41214-ref24">24</xref>] 结果相差较大，考虑两组研究所应用检验试剂及检测方法不同，也不除外地域差异的影响，但两组研究中上述指标的整体变化趋势均是一致，再次验证了红卡治疗对宫颈局部免疫功能的调节作用。</p><p>金舒喜为一种重组干扰素，作为一种免疫调节剂，一方面可以激活自身免疫细胞，例如T淋巴细胞、巨噬细胞、杀伤细胞，减少宫颈分泌物，改善阴道内部环境，发挥调节患者机体免疫能力的作用，一方面可与细胞膜上的干扰素受体相结合，激活抗病毒蛋白基因的表达，通过降解病毒MRNA来抑制病毒多肽链的合成，阻断HPV复制 [<xref ref-type="bibr" rid="hanspub.41214-ref25">25</xref>]，而保妇康栓是由冰片、莪术精练提纯而成的中药制剂，具有生肌止痛、行气破瘀功效，对于宫颈HPV感染有良好治疗效果 [<xref ref-type="bibr" rid="hanspub.41214-ref26">26</xref>]。田赟等人对90例HPV感染者给予干扰素联合保妇康栓治疗，用药3周期(10天为一周期)后HPV转阴率达52.85% [<xref ref-type="bibr" rid="hanspub.41214-ref22">22</xref>]，明显高于本次研究中31.58%的HPV转阴率，考虑与用药疗程持续时间有关。朱文婷等人对于42例宫颈HPV感染者行保妇康栓联合重组人干扰素α-2b凝胶治疗，CD4<sup>+</sup>T升高，而CD8<sup>+</sup>T与CD4<sup>+</sup>/CD8<sup>+</sup>未见明显变化，此结果与本次研究相一致 [<xref ref-type="bibr" rid="hanspub.41214-ref27">27</xref>]。此外，金舒喜联合保妇康栓可提高阴道灌洗液中IL-2、IFN-γ、TNF-α的浓度，降低IL-4的浓度，改善局部免疫功能，这一变化趋势与已发表的相关研究结果大致一致 [<xref ref-type="bibr" rid="hanspub.41214-ref28">28</xref>] [<xref ref-type="bibr" rid="hanspub.41214-ref29">29</xref>] [<xref ref-type="bibr" rid="hanspub.41214-ref30">30</xref>] [<xref ref-type="bibr" rid="hanspub.41214-ref31">31</xref>]。</p><p>本次研究表明，红卡治疗宫颈高危型HPV持续感染的转阴率及有效率均明显高于金舒喜联合保妇康栓治疗，两种治疗均可提高局部IL-2、IFN-γ、TNF-α水平，降低IL-4水平，改善局部免疫功能，其中红卡效果更为显著。两种治疗均可提高外周血中CD4<sup>+</sup>T细胞水平，而红卡纠正甚至逆转CD4<sup>+</sup>/CD8<sup>+</sup>比值，改善了机体整体免疫功能，金舒喜联合保妇康栓对于CD4<sup>+</sup>/CD8<sup>+</sup>改变未见明显效果，分析原因是其局部用药并未达到改善机体全身免疫功能的效果，因此，红卡治疗就改善机体整体免疫功能的效果更为显著。两种治疗均无明显不良反应，相同治疗疗程比较，红卡治疗效果较金舒喜联合保妇康栓更具优势。此前李欢梓等人的研究 [<xref ref-type="bibr" rid="hanspub.41214-ref32">32</xref>] 显示：36例单纯HPV感染患者给予红卡治疗1疗程，4月后治疗有效率48.57%，8月后治疗有效率65.71%，提示红卡治疗作用长远，因本次研究的时间限制，未再进行更为长远的随访，后续会继续对本次研究患者进行追踪报道。此外，红卡治疗价格较金舒喜联合保妇康栓高，会影响HPV感染患者治疗方案的选择；最后红卡治疗均需到医院进行，可能会造成患者依从性下降终止红卡治疗，本次研究组1例患者正是因为未规律来院治疗而退出本次研究。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述：红卡及金舒喜联合保妇康栓治疗均可促进持续感染的宫颈高危型HPV转阴，但红卡提高体内CD4<sup>+</sup>T细胞占比，减轻甚至逆转机体CD4<sup>+</sup>/CD8<sup>+</sup>，改善机体局部甚至全身免疫功能的效果更佳，在临床上，对于因各种原因拒绝红卡治疗的高危型HPV持续感染的患者，金舒喜联合保妇康栓治疗仍是一种好的选择。由于本次研究样本数目有限，关于红卡的治疗作用还需要临床大数据的验证与支持。</p></sec><sec id="s10"><title>文章引用</title><p>梁 欢,邹存华,程菡莹,朱瑞森,赵淑萍. 外用红色诺卡氏菌细胞壁骨架治疗宫颈高危型HPV持续感染的临床疗效及免疫效果评价Evaluation of Clinical Efficacy and Immune Effect of Nocardia Rubra Cell Wall Skeleton for External Use in the Treatment of Persistent Cervical HPV Infection[J]. 临床医学进展, 2021, 11(03): 1241-1249. https://doi.org/10.12677/ACM.2021.113179</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41214-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Jimenez, A.M., Moulick, A., Bhowmick, S., et al. (2019) One-Step Detection of Human Papilloma Viral Infection Using Quantum Dot-Nucleotide Interaction Specificity. Talanta, 205, Article ID: 1201111.  
&lt;br&gt;https://doi.org/10.1016/j.talanta.2019.07.006</mixed-citation></ref><ref id="hanspub.41214-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">王晓静, 张丽颖. 宫颈HPV感染的中西医治疗进展[J]. 中国妇幼保健, 2020, 35(18): 3518-3520.</mixed-citation></ref><ref id="hanspub.41214-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">丁璐, 程忠平. HPV致宫颈癌机制研究进展[J]. 同济大学学报(医学版), 2020, 41(3): 388-393.</mixed-citation></ref><ref id="hanspub.41214-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Berman, T.A. and Cchiller, J.T. (2017) Human Papillomavirus in Cervical Cancer and Oropharyngeal Cancer: One Cause, Two Diseases. Cancer, 123, 2219-2229. &lt;br&gt;https://doi.org/10.1002/cncr.30588</mixed-citation></ref><ref id="hanspub.41214-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">马文擎, 王世宣. 高危型HPV感染的防与治[J]. 实用妇产科杂志, 2020, 36(10): 731-734.</mixed-citation></ref><ref id="hanspub.41214-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Schulmeyer, C.E., Stubs, F., Gass, P., et al. (2020) Correlation between Referral Cytology and In-House Colposcopy-Guided Cytology for Detecting Early Cervical Neoplasia. Archives of Gynecology and Obstetrics, 301, 263-271.  
&lt;br&gt;https://doi.org/10.1007/s00404-019-05389-1</mixed-citation></ref><ref id="hanspub.41214-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Plummer, M., De Martel, C., Vignat, J., et al. (2016) Global Burden of Cancers Attributable to Infections in 2012: A Synthetic Analysis. The Lancet Global Health, 4, e609-e616. &lt;br&gt;https://doi.org/10.1016/S2214-109X(16)30143-7</mixed-citation></ref><ref id="hanspub.41214-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">单玮, 张涛, 张铁军, 赵根明. 我国女性人乳头瘤病毒(HPV)感染的流行病学现状[J]. 中华疾病控制杂志, 2017, 21(1): 89-93.</mixed-citation></ref><ref id="hanspub.41214-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">万雅丽, 黄丹丹, 郭英, 马粉香, 刘跃臣. 人乳头瘤病毒持续性感染与子宫颈癌的研究进展[J]. 现代妇产科进展, 2020, 29(9): 703-705.</mixed-citation></ref><ref id="hanspub.41214-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Tan, S.C., Ismail, M.P., Duski, D.R., et al. (2017) Identification of Optimal Reference Genes for Normalization of RT-qPCR Data in Cancerous and Non-Cancerous Tissues of Human Uterine Cervix. Cancer Investigation, 35, 163-173. &lt;br&gt;https://doi.org/10.1080/07357907.2017.1278767</mixed-citation></ref><ref id="hanspub.41214-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Bhat, S., Kabekkodu, S.P., Varghese, V.K., et al. (2017) Aberrant Gene-Specific DNA Methylation Signature Analysis in Cervical Cancer. Tumor Biology, 39, 101042817694573. &lt;br&gt;https://doi.org/10.1177/1010428317694573</mixed-citation></ref><ref id="hanspub.41214-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, X.A., Zhi, Y.F., Li, Y., et al. (2019) Study on the Relationship between Methylation Status of HPV 16 E2 Binding Sites and Cervical Lesions. Clinica Chimica Acta, 493, 98-103. &lt;br&gt;https://doi.org/10.1016/j.cca.2019.02.027</mixed-citation></ref><ref id="hanspub.41214-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Willemsen, A., Felez-Sanchez, M. and Bravo, I.G. (2019) Genome Plasticity in Papillomaviruses and de Novo Emergence of E5 Oncogenes. Genome Biology and Evolution, 11, 1602-1617. &lt;br&gt;https://doi.org/10.1093/gbe/evz095</mixed-citation></ref><ref id="hanspub.41214-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Warburton, A., Redmond, C.J., Dooley, K.E., et al. (2018) HPV Integration Hijacks and Multimerizes a Cellular Enhancer to Generate a Viral-Cellular Super-Enhancer That Drives High Viral Oncogene Expression. PLOS Genetics, 14, e1007179. &lt;br&gt;https://doi.org/10.1371/journal.pgen.1007179</mixed-citation></ref><ref id="hanspub.41214-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Lima, S.F., Tavares, M.M., Macedo, J.L., et al. (2016) Influence of IL-6, IL-8, and TGF-β1 Gene Polymorphisms on the Risk of Human Papillomavirus-Infection in Women from Pernambuco, Brazil. Memórias do Instituto Oswaldo Cruz, 111, 663⁃669. &lt;br&gt;https://doi.org/10.1590/0074-02760160051</mixed-citation></ref><ref id="hanspub.41214-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">李甜甜, 武丽, 吕霄, 夏建红. 人乳头瘤病毒的感染现况及免疫治疗研究进展[J]. 实用医学杂志, 2019, 35(18): 2862-2867.</mixed-citation></ref><ref id="hanspub.41214-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">徐婉星, 胡小青. 宫颈病变与T淋巴细胞亚群研究进展[J]. 实用临床医学, 2018, 19(10): 100-103+106.</mixed-citation></ref><ref id="hanspub.41214-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">李琦, 陆相辉, 赵薇. HPV不同级别宫颈病变妇女T淋巴细胞亚群的改变分析[J]. 中华医院感染学杂志, 2019, 29(6): 921-924.</mixed-citation></ref><ref id="hanspub.41214-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">朱海燕, 江志泳, 孙庆燕, 刘晶. 宫颈癌患者高危型人乳头瘤病毒感染与免疫功能和癌基因表达的相关性[J]. 中国微生态学杂志, 2019, 31(11): 1322-1325.</mixed-citation></ref><ref id="hanspub.41214-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">潘梅钦, 舒静, 宋爱清, 付文君, 陈素萍, 怀月琴. 外用红色诺卡氏菌细胞壁骨架治疗HPV感染的疗效探讨[J]. 中外医疗, 2019, 38(4): 25-28.</mixed-citation></ref><ref id="hanspub.41214-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">张剑英, 刘班, 张毅敏, 吴杰, 朱静, 潘志文, 熊娟, 陈文虎. 宫颈癌患者外周血中调节性T细胞的变化及其临床意义[J]. 中华微生物学和免疫学杂志, 2015, 35(10): 753-758.</mixed-citation></ref><ref id="hanspub.41214-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">田赟, 李红雨. 红卡与干扰素联合保妇康栓对宫颈HPV感染的疗效[J]. 实用妇科内分泌电子杂志, 2019, 6(13): 121-122+125.</mixed-citation></ref><ref id="hanspub.41214-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">李亚光, 张炜悦, 王伟杰, 魏靖文, 刘恩令. 派特灵治疗宫颈持续HR-HPV感染疗效分析[J]. 华北理工大学学报(医学版), 2020, 22(6): 436-440.</mixed-citation></ref><ref id="hanspub.41214-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">唐金芝. 阴道菌群、宫颈局部T细胞亚群和炎性因子改变对HPV感染的影响[D]: [硕士学位论文]. 南宁: 广西医科大学, 2014.</mixed-citation></ref><ref id="hanspub.41214-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">唐宇星, 王敏. 子宫颈人乳头瘤病毒感染药物治疗研究进展[J]. 中国实用妇科与产科杂志, 2020, 36(12): 1219-1221.</mixed-citation></ref><ref id="hanspub.41214-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">李莹莹. 保妇康栓联合干扰素栓对宫颈HPV感染患者HPV DNA负荷量、炎性因子及免疫功能的影响[J]. 临床合理用药杂志, 2020, 13(2): 26-28.</mixed-citation></ref><ref id="hanspub.41214-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">朱文婷, 马玲, 祝丽霞. 保妇康栓联合重组人干扰素α-2b凝胶对宫颈HPV感染患者HPV转阴率及免疫功能的影响[J]. 中国医学创新, 2020, 17(28): 50-53.</mixed-citation></ref><ref id="hanspub.41214-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">许彩芹, 李艳华, 李颖敏. 扶正解毒汤联合干扰素治疗高危型HPV感染CIN1患者的疗效分析[J]. 中国妇幼保健, 2017, 32(22): 5547-5549.</mixed-citation></ref><ref id="hanspub.41214-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">陈革, 徐宏仙, 许浪萍, 林昌桑, 梁少君. HPV感染宫颈病变患者Th17细胞、IL-2、IL-10、E2F-1蛋白水平及其临床意义[J]. 中华医院感染学杂志, 2020, 30(15): 2357-2361.</mixed-citation></ref><ref id="hanspub.41214-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">张玲玲. 内服外用中药对宫颈HR-HPV感染的治疗和对HR-HPV感染宫颈局部免疫环境影响的临床研究[D]: [硕士学位论文]. 南京: 南京中医药大学, 2017.</mixed-citation></ref><ref id="hanspub.41214-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">贺雯, 任琛琛, 杨立, 刘灵, 李飞燕, 许晴晴, 陈飞, 潘学景. 阴道灌洗液中TNF-α、IL-12、IL-10表达与高危型HPV持续感染的相关性[J]. 现代妇产科进展, 2019, 28(2): 86-89.</mixed-citation></ref><ref id="hanspub.41214-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">李欢梓, 李志玲, 汪艳珠, 麦凤珍, 金玲, 李晴. 红色诺卡氏菌细胞壁骨架治疗宫颈HPV亚临床感染的疗效评价[J]. 中国麻风皮肤病杂志, 2012, 28(3): 161-164.</mixed-citation></ref></ref-list></back></article>